Relief of withdrawal symptoms is a meaningful outcome to measure, but it is not interchangeable with evidence of reduced methamphetamine consumption. A historical replacement-therapy trial illustrates why both outcomes belong in a research summary.
The tested regimen and the null use result
Galloway and colleagues’ 2011 randomized, double-blind trial enrolled 60 treatment-seeking adults with methamphetamine dependence. Participants received oral sustained-release dextroamphetamine 60 mg/day or placebo for eight weeks, with psychosocial treatment. After the first day, the daily dose was divided into two equal doses.
Methamphetamine urine testing occurred twice weekly, using an initial 1,000 ng/mL cutoff and GC–MS quantification of positive specimens. The number of methamphetamine-negative samples did not differ significantly (p=0.894), nor did self-reported abstinent days (p=0.842). Withdrawal and craving scores favored dextroamphetamine in the reported models. No serious adverse events were reported.
Why an amphetamine prescription does not invalidate a methamphetamine outcome
The study assessed methamphetamine, rather than simply counting every amphetamine-class result as continued methamphetamine use. This analytical distinction is essential to interpreting a trial in which the assigned medication itself is dextroamphetamine.
For any comparable laboratory record, the first question is what the assay reports: a drug class, a specified parent compound or a metabolite. A result for one of those categories should not silently become a result for another. The specimen method and confirmation procedure determine which comparison is defensible.
The study cutoff also defines its negative category. A specimen below that boundary does not establish that it contains no methamphetamine at any concentration, and it cannot establish uninterrupted abstinence between collection times. That is a limitation on the classification’s meaning, rather than a reason to discard the classification.
Can craving be treated as a surrogate for abstinence?
If reduced craving is proposed as a substitute for reduced use, the relationship must be demonstrated rather than assumed. Here the reported outcomes point in different directions: symptom measures favored medication, while the measured use comparisons did not establish superiority.
That pattern supports asking further research questions about symptom relief and the conditions under which it might influence behavior. It does not show that symptom improvement inevitably produces abstinence. Nor does the use null demonstrate that withdrawal relief was imaginary or unimportant.
The trial was small and brief, and its adverse-event experience cannot establish long-term or uncommon-risk estimates. It supplies historical evidence about the tested regimen in selected participants, without establishing a current prescribing instruction or a general prediction for every person with methamphetamine use disorder.
Source
Galloway GP, et al. A randomized, placebo-controlled trial of sustained-release dextroamphetamine for treatment of methamphetamine addiction. Clin Pharmacol Ther. 2011;89:276–282. doi:10.1038/clpt.2010.307. Full text.